CD40L-treated immune cells for advanced lung cancer with certain gene changes
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 study tests a lab-made immune cell treatment (TIL) boosted with CD40L, plus nivolumab, for stage IV or returning non-small cell lung cancer with specific gene changes (EGFR, ALK, ROS1, or HER2). It aims to help your immune system attack the cancer after it has grown despite standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have stage IV or recurrent non-small cell lung cancer with gene changes in EGFR, ALK, ROS1, or HER2 (ERBB2)
- Have had the cancer grow after at least one prior cancer treatment, including the right targeted therapy when it usually fits your gene change
- Be able to have tumor tissue collected: a reachable tumor for biopsy that should provide enough tissue for cell manufacturing
- Have good enough overall health: energy level (ECOG) 0–1, expected survival at least 4 months, and blood organ test results in allowed ranges
- Not have had prior PD-1/PD-L1 immune checkpoint treatment for metastatic lung cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.
This trial tests a new way to boost your immune cells after they are collected from your tumor and grown in a lab. Instead of high-dose IL-2, you would get a modified version called ANV419, which may have fewer side effects.
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
This trial tests a new way to treat advanced melanoma by taking immune cells from your tumor, enhancing them in the lab to fight better, and giving them back to you. It is for people whose melanoma has spread or cannot be removed, and who have already tried standard treatments.
This Phase 2 study tests a T-cell–based immunotherapy for people with metastatic non-small cell lung cancer that has grown despite prior treatment. It may help your immune system recognize and fight your cancer using cells made from your tumor.
This trial tests a new immune therapy using your own white blood cells (tumor-infiltrating lymphocytes) to treat non-small-cell lung cancer that has come back or grown. If you have multiple lung spots or your cancer has progressed after surgery or targeted therapy, this study may offer a treatment option.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.